Bone and kidney disease: Diagnostic and therapeutic implications

Current Rheumatology Reports

Volumn 14, Issue 3, 2012, Pages 217-223

  Jamal, Sophie A ^a   West, Sarah L ^a   Miller, Paul D ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Bone disease; Bone mineral density; Chronic kidney disease; Diagnostic; Fractures; Osteoporosis; Therapeutic; Treatment

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE;

BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DIALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; MALE; MINERAL METABOLISM; NON INVASIVE PROCEDURE; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; HUMANS; OSTEOPOROSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84860709238     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0243-9     Document Type: Review

References (42)

1. Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167 (2):133-9. (Pubitemid 46148060)
2. Jamal SA, Swan VJ, Brown JP, et al. Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. Am J Kidney Dis. 2010;55(2):291-9.
3. Miller PD. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol. 2009;29(2):144-55.
4. Kidney Disease Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76 suppl 113:s1-130.
5. •• Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829-35. This is a post-hoc analysis examining the effects of denosumab on fracture by stage of CKD. Denosumab is of particular interest in CKD because it is not cleared by the kidney.
6. Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007;18(1):59-68. (Pubitemid 44885496)
7. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20:2105-15. (Pubitemid 41698774)
8. Ishani A, Blackwell T, Jamal SA, et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7):1430-8.
9. Nickolas TL, Stein E, Cohen A, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21(8):1371-80.
10. •• Nickolas TL, Cremers S, Zhang A, et al. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol. 2011;22:1560-72. This was a comprehensive cross-sectional study that examined factors associated with fracture in stages 3 to 5 CKD.
11. Jamal SA, Cheung AM, West SL, Lok CE. Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporosis Int. 2012. doi:10.1007/s00198-012-1908-y.
12. Melton 3rd LJ, Riggs BL, van Lenthe GH, et al. Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res. 2007;22(9):1442-8. (Pubitemid 351339689)
13. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis. 2007;49(5):674-81. (Pubitemid 46654494)
14. Duan Y, De Luca V, Seeman E. Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J Clin Endocrinol Metab. 1999;84:718-22. (Pubitemid 29075711)
15. Christiansen P, Steiniche T, Brockstedt H, et al. Primary hyperparathyroidism: iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone. 1993; 14:755-62. (Pubitemid 23294029)
16. Dolgos S, Hartmann A, Bonsnes S, et al. Determinants of bone mass in end-stage renal failure patients at the time of kidney transplantation. Clin Transplant. 2008;22(4):462-8.
17. Ersoy FF, Passadakis SP, Tam P, et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab. 2006;24(1):79-86. (Pubitemid 41821508)
18. Elder GJ, Mackun K. 25-hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res. 2006;21(11):1778-84. (Pubitemid 46141233)
19. Ambrus C, Almasi C, Berta K, et al. Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol. 2011;43(2):475-82.
20. Jamal SA, Gilbert J, Gordon C, Bauer DC. Cortical PQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006;21:543-8.
21. Russo CR, Taccetti G, Caneva P, et al. Volumetric bone density and geometry assessed by peripheral quantitative computed tomography in uremic patients on maintenance hemodialysis. Osteoporos Int. 1998;8(5):443-8. (Pubitemid 28486712)
22. Hasegawa K, Hasegawa Y, Nagano A. Estimation of bone mineral density and architectural parameters of the distal radius in hemodialysis patients using peripheral quantitative computed tomography. J Biomech. 2004;37:751-6. (Pubitemid 38445037)
23. Negri AL, Barone R, Lombas C, et al. Evaluation of cortical bone by peripheral quantitative computed tomography in continuous ambulatory peritoneal dialysis patients. Hemodial Int. 2006;10(4):351-5. (Pubitemid 44489918)
24. Cejka D, Patsch JM, Weber M, et al. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol. 2011;6(9):2264-71.
25. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. (Pubitemid 44967731)
26. Vassalotti JA, Uribarri J, Chen SC, et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S56-68. (Pubitemid 351444717)
27. Meier C, Seibel MJ, Kraenzlin ME. Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res. 2009;24 (3):386-8.
28. Lehmann G, Ott U, Kaemmerer D, et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol. 2008;70(4):296-305.
29. Hutchison AJ, Whitehouse RW, Boulton HF, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993;44 (5):1071-7. (Pubitemid 23316476)
30. Carmen Sanchez M, Auxiliadora Bajo M, Selgas R, et al.: Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000, 36:953-61.
31. Couttenye M, D'Haese P, VanHoof V, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transpl. 1996;11:1065-72. (Pubitemid 26182500)
32. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;26 (4):622-31.
33. Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis endstage renal failure patients. Am J Kidney Dis. 2003;41(5):997-1007. (Pubitemid 36532134)
34. Barreto FC, Barreto DV, Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73(6):771-7. (Pubitemid 351323258)
35. Jamal SA, Leiter RE, Jassal V, et al. Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporosis Int. 2006;17(9):1390-7. (Pubitemid 44127326)
36. West SL, Jamal SA, Lok CE: Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2011, E-pub ahead of print.
37. Danese MD, Kim J, Doan QV, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47(1):149-56. (Pubitemid 41828277)
38. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70 (7):1358-66. (Pubitemid 44435190)
39. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42 suppl 3:S1-202.
40. Miller PD: A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Therapeutic Advances in Musculoskeletal Disease 2011, E-pub ahead of print.
41. Klawansky S, Komaroff E, Cavanaugh PFJ, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int. 2003;14:570-6. (Pubitemid 36975556)
42. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22 (4):503-8. (Pubitemid 47457426)